Investigating the mechanisms of platelet activation

Investigating the mechanisms of platelet activation - IMPA-Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00038697

Enrollment

250

Registered

2025-12-10

Start date

2024-06-06

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pathophysiological processes of platelet activation

Interventions

Group 1: Venous blood samples from healthy volunteers (between 18 - 60 years old, according to inclusion and exclusion criteria)

sample analyses ex vivo

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: -Capacity to consent -Participation in the study < 2 times per month (2-week intervals)

Exclusion criteria

Exclusion criteria: -Refusal to participate in the study -Taking (regularly or in the short term, i.e., within 7 days prior to blood collection) of medications that can affect platelet aggregation (including aspirin, ibuprofen, SSRI and SNRI antidepressants) -Known platelet dysfunction or thrombocytopenia -Pregnancy and breastfeeding -Participation in the study > 2 times per month

Design outcomes

Primary

Measure	Time frame
Function of S1P (Sphingosine-1-phosphate) for platelet activation	—

Secondary

Measure	Time frame
Function of specific S1P receptors 1-5 for platelet activation	—

Countries

Germany

Contacts

Public ContactBernhard Rauch

Carl von Ossietzky Universität Oldenburg

bernhard.rauch@uni-oldenburg.de0441 798 4930

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026